CSF2 and chronic kidney disease: Clinical trials evaluating the efficacy and safety of GM-CSF as an adjuvant to hepatitis B vaccine in patients with end-stage renal disease showed improved seroprotection rates with HBV vaccine after GM-CSF administration [27].